By Ellen Capon (Drug Target Review)2023-11-07T14:45:12
New pathway involved in cellular protein degradation could develop LYTACs therapy and find new treatments for lysosome shortage disorders.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-02-20T14:00:43Z
2026-02-10T14:41:15Z
2023-09-06T16:55:04
Sponsored by NanoTemper Technologies
2023-07-04T10:05:58
Sponsored by Revvity
2025-05-14T14:30:00
Sponsored by Abzena
2024-03-08T10:00:25
Sponsored by Molecular Devices
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
Site powered by Webvision Cloud